ACAD ACADIA Pharmaceuticals
- 15.275
- +0.415+2.79%
ACADIA Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON).
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
ACADIA Pharmaceuticals (ACAD) has an average rating of outperform and price targets ranging from $13 to $39, according to analysts polled by Capital IQ. Price: 15.45, Change: +0.24, Percent Change: +1
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities
ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
B of A Securities: Maintaining the ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $26.00 to $22.00.
B of A Securities: Maintaining the ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $26.00 to $22.00.
B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $26 to $22.
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk
0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m.
ACADIA Pharmaceuticals | 10-Q: Quarterly report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30.19 to $30.
Earnings Call Summary | ACADIA Pharmaceuticals(ACAD.US) Q1 2024 Earnings Conference
The following is a summary of the ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript:Financial Performance:ACADIA Pharmaceuticals reported Q1 revenue of $205.8 million, a 74% increase
Analysis
Price Target
No Data
